Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 33.6591
- Book/Share -1.4667
- PB -149.3591
- Debt/Equity -26.0193
- CurrentRatio 0.7245
- ROIC 0.187
- MktCap 393541602944.0
- FreeCF/Share 11.6078
- PFCF 19.1328
- PE 164.8315
- Debt/Assets 0.5134
- DivYield 0.0295
- ROE 4.9875
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABBV | Wolfe Research | Outperform | Peer Perform | -- | -- | Jan. 8, 2026 |
| Resumed | ABBV | UBS | -- | Neutral | -- | $240 | Jan. 7, 2026 |
| Upgrade | ABBV | HSBC Securities | Hold | Buy | -- | $265 | Dec. 10, 2025 |
| Initiation | ABBV | Scotiabank | -- | Sector Outperform | -- | $280 | Nov. 13, 2025 |
| Downgrade | ABBV | DZ Bank | Buy | Hold | -- | $237 | Nov. 4, 2025 |
| Downgrade | ABBV | Erste Group | Buy | Hold | -- | -- | Oct. 14, 2025 |
| Downgrade | ABBV | HSBC Securities | Buy | Hold | -- | -- | Oct. 1, 2025 |
| Upgrade | ABBV | Berenberg | Hold | Buy | -- | $270 | Sept. 17, 2025 |
| Resumed | ABBV | Piper Sandler | -- | Overweight | -- | $231 | Aug. 12, 2025 |
| Upgrade | ABBV | Daiwa Securities | Neutral | Outperform | -- | $214 | Aug. 7, 2025 |
News
AbbVie: The Dividend Does Not Lie
Published: January 08, 2026 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. maintains its Hold rating, as its latest dividend raise signals near-term earnings pressure and a decelerating growth trend. ABBV's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Current valuation appears stretched, with ABBV stock trading at 23.5x P/E and a PEGY ratio of 1.41x.
Read More
AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
Published: January 07, 2026 by: Reuters
Sentiment: Positive
AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Read More
AbbVie Near Deal for Revolution Medicines
Published: January 07, 2026 by: WSJ
Sentiment: Positive
The cancer-drug biotech firm has a market value around $16 billion.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
What Can Trigger A Breakout In Abbvie Stock?
Published: January 06, 2026 by: Forbes
Sentiment: Positive
AbbVie stock (NYSE:ABBV) has exhibited considerable rally potential, having once achieved over a 50% increase in less than two months in 2020. Furthermore, the stock has undergone seven rallies surpassing 30% within comparable periods, including significant years such as 2017 and 2024.
Read More
Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth
Published: January 02, 2026 by: Zacks Investment Research
Sentiment: Positive
ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.
Read More
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Best Dividend Aristocrats For January 2026
Published: December 31, 2025 by: Seeking Alpha
Sentiment: Positive
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.
Read More
3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.
Read More
ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Negative
AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.
Read More
5 Big Drug Stocks That May Continue to Outperform in 2026
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
Read More
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Published: December 22, 2025 by: The Motley Fool
Sentiment: Positive
AbbVie is a Dividend King that successfully navigated a challenging patent cliff. Coca-Cola is a household name that has survived and thrived for 139 years.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc
Published: December 17, 2025 by: CNBC Television
Sentiment: Neutral
Market movers: The Investment Committee's top stocks to watch right now.
Read More
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
How AbbVie's Pipeline Is Lining Up Key Product Launches
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions.
Read More
This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence
Published: December 10, 2025 by: 24/7 Wall Street
Sentiment: Positive
Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, policy uncertainties around drug pricing, and a surge in tech-driven gains from the AI boom.
Read More
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.
Read More
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
Published: November 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV), jointly with the adMare BioInnovations, announced the launch of the AbbVie Biotech Innovators Award, a prize to help foster innovation and support growth in Quebec's life sciences sector.
Read More
2 Dividend Stocks to Hold Through Any Market Cycle
Published: November 19, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Trying to build a portfolio that can survive recessions, inflation, and market volatility is one of the biggest challenges any investor can face.
Read More
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.
Read More
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
- EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available for patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy - In the Phase 3 EPCORE® FL-1 trial, EPKINLY + R2 demonstrated significantly superior progression-free survival and overall response rates compared to standard of care R2 with approximately 3 out of 4 patients achieving a complete response - Approval marks third indication for EPKINLY and first-ever FDA approval for a bispecific combination therapy in lymphoma NORTH CHICAGO, Ill. , Nov. 18, 2025 /PRNewswire/ -- …
Read More
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.
Read More
It's Best Time In 10 Years To Lock In Income: Our Picks
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Positive
Investors can now access 4–7% from top-quality REITs, 3.5%+ from dividend ETFs, and 6%+ from midstream infrastructure — without taking on excessive risk. While the S&P 500 is up ~110% since 2020, 70–80% of returns come from the Mag7, leaving broad-market returns near inflation levels. US inflation sits at 3%, and Western Europe reports 3.5–4%, emphasizing the need for income-producing assets to preserve purchasing power for retirees.
Read More
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Published: November 14, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Read More
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance?
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.
Read More
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript
Published: October 31, 2025 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. ( ABBV ) Q3 2025 Earnings Call October 31, 2025 9:00 AM EDT Company Participants Elizabeth Shea - Senior Vice President of Investor Relations Robert Michael - CEO & Chairman of the Board Jeffrey Stewart - Executive VP & Chief Commercial Officer Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Scott Reents - Executive VP & CFO Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Matthew Phipps - William Blair & Company L.L.C., Research …
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Robert A. Michael
- Employees 55000